Aspect Biosystems CEO Tamer Mohamed will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference to be held May 5-6, 2025 in Toronto, ON.
The 2025 Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.
The following are specific details regarding Aspect Biosystems’ presentation:
| Aspect Biosystems Company Presentation | |
| Date | Monday, May 5, 2025 |
| Time | 11:30am EDT |
| Location | Metro Toronto Convention Centre, Room 104 A
|
For more information, please visit: www.bloomburton.com/conference.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.
Contact
Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com